Satish Jindal
General Partner @ Advent Life Sciences
Cambridge, United States
Satish Jindal is a General Partner at Advent Life Sciences. He previously worked at Antolrx Pharmaceuticals as a Board Member and Co-founder. Satish Jindal attended the Massachusetts Institute of Technology.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Satish Jindal invests in
Stages Satish Jindal invests in
Countries Satish Jindal invests in
Investment Focus
Industry
- Biotechnology 2 (100%)
- Biopharma 1 (50%)
- Life Science 1 (50%)
- Therapeutics 1 (50%)
Stage
- Seed 1 (50%)
- Series A 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Epitopea
|
Epitopea is a transatlantic biotechnology company developing transformational immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. Cryptigen™ TSAs are discovered by a proprietary approach deploying immunopetidomics, mass spectrometry, genomics, andbioinformatics, which allows the identification of conserved, aberrantly-expressed, tumour-specific antigens, hidden in cancer's 'junk' DNA. These hidden Cryptigen™ TSAs have been identified by research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal. | $31M / Seed / Oct 24, 2024 | |
Amphista Therapeutics
|
Amphista Therapeutics operates as a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body's natural processes to selectively and efficiently degrade and remove disease causing proteins. | $7.5M / Series A / Apr 07, 2020 |
Co-Investors
About Advent Life Sciences
Advent Life Sciences is a venture team investing in life sciences businesses. The team consists of 11 professionals with extensive scientific, medical and operational experience, and a long-standing track record of entrepreneurial and investment success across the UK, Europe and the US. The Firm invests in a range of sectors within life sciences,principally in new drug discovery, enabling technologies, and med tech. Realizations in the last three years include Algeta, Avila, CN Creative, EUSA, Micromet. Current investments include Acutus, Biocartis, Cellnovo, f2G, NeRRe,
Advent Life Sciences Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andrew J Wood
Venture Partner
|
|||
Dale Pfost
General Partner
|
|||
Kaasim Mahmood
General Partner
|
|||
|
Satish Jindal
General Partner
|
|||
Shahzad Malik
General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Satish Jindal invest in?
Satish Jindal invests primarily in Biotechnology, Biopharma and Life Science startups, most often at Seed and Series A stage. Most of the 2 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Satish Jindal last invest?
The most recent investment recorded for Satish Jindal closed in Oct 2024. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
